ALVAL.PA · Valbiotis SA
-
-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | FR0013254851 |
| CurrencyCode | EUR |
| Exchange | PA |
| Beta | 0.5 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 10.9 |
| PE Ratio | None |
| Market Cap | 49M |
ABOUT
Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Learn More